Answers are grounded in this paper and cite their sources.
The current research presents the formulation of losartan potassium-loaded biomucoadhesive-floating beads using sodium alginate (matrix-former), linseed polysaccharide (biomucoadhesive polymer) and calcium silicate (floatation-improving material). These losartan potassium-loaded beads showed 63.86 ± 0.93 to 95.33 ± 2.14% drug entrapment efficiency, 1.44 ± 0.04 to 1.72 ± 0.08 mm bead-size and 0.65 ± 0.06 to 0.81 ± 0.06 g/cm3 density. The biomucoadhesive-floating beads were characterized by SEM, FTIR and p-XRD. In gastric pH, losartan potassium-loaded beads presented excellent buoyancy, in vitro drug releasing over 10 h and good biomucoadhesivity. These biomucoadhesive-floating beads could be profitable to prolong gastroretention with sustained drug releasing.
No takes yet. Share an insight, caveat, or question.
Behera et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: